Laboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China; Department of Pulmonary and Critical Care Medicine, Chengdu Institute of Respiratory Health, Chengdu Third People's Hospital Branch of National Clinical Research Center for Respiratory Disease, Chengdu, China; State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science & Technology, Taipa, Macao Special Administrative Region of China.
Laboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China; Department of Pulmonary and Critical Care Medicine, Chengdu Institute of Respiratory Health, Chengdu Third People's Hospital Branch of National Clinical Research Center for Respiratory Disease, Chengdu, China.
Pharmacol Res. 2022 Aug;182:106286. doi: 10.1016/j.phrs.2022.106286. Epub 2022 Jun 2.
Pulmonary fibrosis (PF) is the pathological change of end-stage interstitial lung diseases with high mortality and limited therapeutic options. Lung macrophages have distinct subsets with divergent functions, and play critical roles in the pathogenesis of PF. In this study, integrative analysis of lung single-cell and bulk RNA-seq data from patients with fibrotic hypersensitivity pneumonitis and idiopathic pulmonary fibrosis was utilized to identify particular macrophage subsets during the development of PF. We find a specific macrophage subpopulation highly expressing PLA2G7 in fibrotic lungs. We performed additional single-cell RNA-seq analysis to identify analogous macrophage population in bleomycin (BLM)-induced mouse pulmonary fibrosis models. By in vitro and in vivo experiments, we further reveal the pro-fibrotic role for this PLA2G7 macrophage subset in fibroblast-to-myofibroblast transition (FMT) during pulmonary fibrosis. PLA2G7 promotes FMT via LPC/ATX/LPA/LPA2 axis in macrophages. Moreover, PLA2G7 is regulated by STAT1, and pharmacological inhibition of PLA2G7 by Darapladib ameliorates pulmonary fibrosis in BLM-induced mice. The results of this study support the view that PLA2G7 macrophage subpopulation contributes importantly to the pathogenesis of PF, which provides a potential way for targeted therapy.
肺纤维化 (PF) 是一种终末期间质性肺疾病的病理变化,其死亡率高,治疗选择有限。肺巨噬细胞具有不同的亚群,具有不同的功能,在 PF 的发病机制中发挥着关键作用。在这项研究中,我们整合了纤维化性过敏性肺炎和特发性肺纤维化患者的肺单细胞和批量 RNA-seq 数据,以鉴定 PF 发展过程中特定的巨噬细胞亚群。我们发现纤维化肺中高度表达 PLA2G7 的特定巨噬细胞亚群。我们进行了额外的单细胞 RNA-seq 分析,以鉴定博来霉素 (BLM) 诱导的小鼠肺纤维化模型中的类似巨噬细胞群体。通过体外和体内实验,我们进一步揭示了该 PLA2G7 巨噬细胞亚群在肺纤维化过程中向成肌纤维细胞转化 (FMT) 中的促纤维化作用。PLA2G7 通过巨噬细胞中的 LPC/ATX/LPA/LPA2 轴促进 FMT。此外,PLA2G7 受 STAT1 调控,达普拉地布通过抑制 PLA2G7 可改善 BLM 诱导的小鼠肺纤维化。这项研究的结果支持 PLA2G7 巨噬细胞亚群对 PF 发病机制有重要贡献的观点,为靶向治疗提供了一种潜在途径。